SAN DIEGO, Sept. 30 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that it will host a live webcast of its Analyst Day on Wednesday, October 7, 2009 at 11:30 a.m. Eastern Time. Cadence's senior management team, led by Ted Schroeder, President and Chief Executive Officer, will provide an overview of the clinical data and market opportunity for the Company's investigational product candidate, Acetavance(TM) (intravenous acetaminophen), which is currently under Priority Review by the U.S. Food and Drug Administration for the treatment of acute pain and fever.
Scheduled Analyst Day guest speakers include:
The webcast will be available via the Investor Relations page on the Company's website at www.cadencepharm.com. A replay of the webcast will be archived on the company's website beginning approximately two hours following the live event.
In addition, Mr. Schroeder and other members of the Cadence management team will preside over the NASDAQ opening ceremony on Tuesday, October 6, 2009 at NASDAQ's MarketSite in Times Square in New York City. A live webcast of the ceremony will be available at http://www.nasdaq.com/reference/marketsite_about.stm.
Acetavance is Cadence Pharmaceuticals' proprietary intravenous formulation of acetaminophen. Acetaminophen is the most widely used medication for the treatment of pain and fever in the United States and is available in more than 600 combination and single-ingredient prescription and over-the-counter products. Cadence acquired the exclusive rights to Acetavance in the United States and Canada in 2006 from Bristol-Myers Squibb Company, which markets the product as Perfalgan in Europe and other parts of the world. Intravenous acetaminophen is approved in approximately 80 countries, including major markets in Europe, where the product is the market leader among all injectable analgesics. Approximately 90 million vials of intravenous acetaminophen were sold in Europe in 2008 representing an increase of approximately 13% over 2007.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company is currently developing Acetavance (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever. For more information about Cadence's pipeline, visit www.cadencepharm.com.
Statements included in this press release that are not a description of historical facts are forward-looking statements that are based on Cadence's current beliefs and expectations. The inclusion of forward-looking statements such as these should not be regarded as a representation by Cadence that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the company's business, including, without limitation: the company's dependence on its only product candidate, Acetavance, and the possibility that the FDA may determine that the data and information provided in the NDA for Acetavance are insufficient to support regulatory approval; intense competition from existing and new products, which could diminish the commercial potential for Acetavance; the possibility that the patent rights covering Acetavance may not be sufficient to preclude other intravenous formulations of acetaminophen from being developed by competitors; the potential for Cadence to require substantial additional funding in order to obtain regulatory approval for and commercialize Acetavance, and the risk that the company may not be able to raise sufficient capital when needed, or at all; and other risks detailed in Cadence's prior press releases as well as in Cadence's periodic public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Cadence(TM) and Acetavance(TM) are trademarks of Cadence Pharmaceuticals, Inc.
For Further Information: William R. LaRue SVP, CFO Cadence Pharmaceuticals, Inc. 858-436-1400 or Rebecca Birbach Burns McClellan 212-213-0006 firstname.lastname@example.org
SOURCE Cadence Pharmaceuticals, Inc.
|SOURCE Cadence Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved